Overview

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-03-31

Target enrollment:

Participant gender:

Summary

This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to maintain asthma control in Chinese patients.

Phase:

PHASE3

Details

Lead Sponsor:

AstraZeneca

Treatments:

benralizumab